MM&M Hall of Femme deadline Jan. 22; Amarin launches heart health education campaign; Infographic: Younger generations and health insurance.
The FDA is using less-stringent methods to get drugs approved faster, study finds; FTC member endorses Medicare drug negotiation; Planned Parenthood launches largest electoral effort.
JPM attendees believe digital health lacks clear definition; MM&M Hall of Femme deadline extension; Celgene exec joins Bluebird Bio.
Rochester Drug Co-Operative will stop distributing opioids; SmileDirectClub to begin selling aligners to orthodontists; Eli Lilly to sell more insulin at half price.
Biogen to buy early-stage Alzheimer’s treatment; Oklahoma sues drug distributors; HHS urges appeals court to reinstate its TV list price disclosure rule.
23andMe makes first deal to develop drugs based on its genetic data; Oklahoma settles another opioid lawsuit; Eli Lilly to acquire Dermira for $1.1 billion.
AbbVie to create subsidiary for Allergan’s aesthetics products; California plans to sell its own generic drugs; BMS and Sanofi sue Hawaii over free speech.
Drug stores sue doctors over opioid crisis; Cancer death rate sees biggest drop; Walgreens misses earnings expectation.
Sen. Grassley tries to win over Democrats to his drug pricing bill; Study showed no clear link between talc and ovarian cancer; A look at health gadgets at CES.
Gwyneth Paltrow’s Goop is coming to Netflix; Juul to undergo $1 billion restructuring; Merck’s Keytruda shows mixed results in lung cancer trial.
FDA may add menthol to banned vape flavors if teens start using it; States appeal ACA case to the Supreme Court; New Mexico sues J&J over baby powder.
FDA bans some flavored vapes; Drugmakers hike prices on hundreds of drugs; Google’s DeepMind beats doctors in diagnosing breast cancer.